Skip to main content
. Author manuscript; available in PMC: 2014 Jul 12.
Published in final edited form as: Adv Mater. 2013 Apr 15;25(26):10.1002/adma.201300343. doi: 10.1002/adma.201300343

Figure 2.

Figure 2

(a) Confocal microscopy demonstrates anti-EGFR antibody targeting increases uptake by EGFR-overexpressing MDA-MB-231 cells as compared to non-EGFR-overexpressing MCF-7 cells and non-specific antibody targeting. (b) Increased uptake of EGFR-targeted NDLPs was observed across multiple concentration (*p<10−4, **p<10−5, ***p<10−6, 2-way ANOVA for targeted vs. untargeted, within MDA-MB-231 p=1.35×10-19, within MCF-7 p=3.36×10-16, 4 degrees of freedom). (c) Pre-treatment with EGF diminished uptake of EGFR-targeted NDLPs in a dose dependent fashion, indicating receptor dependent uptake (*p<0.005, **p<10−5, ***p<10- 6). (d) Treatment with anti-EGFR targeted, epirubicin-loaded NDLPs reduced cell viability in both cell lines, however the effect was only significant in the EGFR-overexpressing MDA-MB-231 cells (*p<0.05).